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The Passerini reaction of -hydrazino acids, carbonyl compounds and isocyanides yielded hydrazino depsipeptides, a new 
class of backbone extended peptidomimetics comprising amide bond isoster. A wide range of carbonyl and isocyano 
components were used along the -hydrazino acids carrying three different N protecting groups. The kinetics and 
thermodynamic equilibrium of the rate-determining step of the reaction with different -hydrazino acids were studied by 
DFT approach.  
Introduction 
Screening of small-molecule libraries has been the most 
commonly used tool in drug discovery over the past two 
decades.
1
 However, most libraries lack diversity in terms of 
biological and chemical properties, i.e. “chemical space” 
covered is infinitely small. Contrary to that, natural products 
with complex molecular architectures and numerous 
stereogenic centers represent valuable pool of drug 
candidates.
2
 Therefore, access to libraries of natural product-
like compounds with high degree of structural diversity is 
important for development of novel leads needed to tackle 
new generations of biological targets.
3 
 Natural products that contain an N-N bond compose of a 
fascinating group of compounds with a tremendous variety of 
structures and biological activities.
4
 Among them are 
compounds that contain -hydrazino acid motif, like antibiotic 
negamycine,
5
 the B6 vitamin antagonist linatine
6
 and 
numerous peptides with embedded cyclic hydrazine skeleton - 
piperazic acid.
7
 Synthetic hydrazino peptidomimetics show 
enhanced stability toward proteolytic enzymes and extended 
pharmacokinetic properties,
8
  exhibit antimicrobial
9
 and 
proteasome inhibition activity.
10
 Also, hydrazino 
peptidomimetics show high propensity toward specific 
secondary structure known as hydrazino-turn, an eight-
membered hydrogen-bonded pseudo-cycles.
8
 Ability to adopt 
well-defined folded structures is an important feature for 
various biomedical applications, but also construction of 
functional materials. Thus, incorporation of only one 
hydrazino-derivative of trans-2-aminocyclobutanecarboxilyc 
acid caused stabilization of 8-helix over 12-helix conformation 
for an oligomer length up to 6 residues.
11
  Also, heterochiral 
cyclic oligomers composed of 1:1 mixture of -amino acids and 
-hydrazino acids self-assemble into nanotubular structures in 
solution and solid phase.
12
 We have recently designed a small 
series of hydrazino peptidomimetics and showed that their 
interaction with DNA and RNA can be finely modulated with 
the number and relative position of α-hydrazino acid(s) within 
the peptide chain.
13
 
Since wider utilization of hydrazino peptidomimetics 
depends on easy access to the libraries of compounds, we are 
interested in developing reliable strategies for fast 
construction of structurally distinct compounds based on -
hydrazino acid motif. Multicomponent reactions (MCRs) offer 
numerous advantages over traditional sequential reactions for 
the synthesis of diverse structurally demanding compounds.
14
 
MCRs were applied in the synthesis of small drug-like molecule 
libraries,
15
 but also large and more complex molecules.
16
 
Isocynide-based MCRs, particularly Passerini and Ugi reactions, 
are of special importance, because they provide peptide-like 
compounds.
14b,17
 The utility of the Passerini reaction relays on 
the mild reaction conditions required for the condensation of a 
carbonyl compound, a carboxylic acid and an isocyanide to 
afford -acyloxycarboxamides  depsipeptides.
14b
 Many 
naturally occurring depsipeptides have a wide range of 
biological activity,
18
 therefore, depsipetides are considered a 
lead compounds in the drug development process,
19
 but also 
promising polymers for biomedical applications.
20
 Since 
backbone structure of the Passerini product is influenced 
mainly by the carboxylic component,
21
 introduction of -
hydrazino acid as a carboxylic component could yield a novel 
class of peptidomimetics  hydrazino depsipeptides. These 
peptidomimetics that bear two distinct structural features: 
backbone extension steaming from the hydrazino acid 
component and amide bond isoster as a result of the Passerini 
reaction (Scheme 1).  
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Scheme 1 
Results and Discussion 
 
N-Terminal position of -hydrazino acid-derived part in the 
Passerini product (Scheme 1) allows further modification 
through some other MCR or a standard peptide coupling 
procedure, therefore three types of -hydrazino acids were 
used in this study. N-benzyl, N
β
-Boc protected hydrazino acids 
(type I, Scheme 2) were obtained by electrophilic amination of 
the corresponding N-benzyl-L-amino acid with N-Boc 
oxaziridine.
22 
Nucleophilic substitution of D-amino acid-derived 
-bromo acid with Boc-hydrazine yielded N
β
-Boc protected -
hydrazino acids,
23
 where N position was further protected 
with Boc (type II) or Cbz group (type III, Scheme 2).
24
 Also, 
hydrazino proline derivative, Boc-hPro-OH (Scheme 2) was 
used to explore the utility of cyclic acid components in the 
Passerini reaction. 
 
 
 
Scheme 2. 
 
In order to introduce -hydrazino acid in the Passerini 
reaction, we performed a model reaction with N-benzyl, N
β
-
Boc protected hydrazino-L-leucine, p-nitro benzaldehyde and 
methyl 2-isocyano-3-phenylpropanoate in order to optimize 
reaction conditions. First reaction performed in dry 
dichloromethane under argon for 24 h gave the corresponding 
Passerini product 1 in 40 % yield (Table 1, Entry 1). Encouraged 
by this result, we optimized reaction conditions by testing 
different solvents and found tetrahydrofurane as the most 
appropriate solvent for the Passerini reaction (54 %, Entry 3). 
Performing reaction at 50 °C in THF failed to improve the yield 
of 1 (Entry 5). Bousquet et al. described a convenient and 
efficient Passerini multicomponent reaction under solvent-free 
conditions at high temperature,
25
 therefore, we examined the 
effect of solvents on the course of the reaction. The solvent-
free reaction carried out at 80 °C gave Passerini product 1 in 31 
% yield (Entry 6). Therefore, optimal conditions for the 
Passerini reaction with -hydrazino acids were THF as a 
solvent at room temperature for 24 h. With optimized 
conditions in hand, we set out to test the scope of the protocol 
with different oxo-compounds, isocyanides and -hydrazino 
acids. 
 
Table 1. Optimization of the Passerini reaction.a  
 
Entry Solvent T [°C] Yield [%]b 
1 Dichloromethane RT 40 
2 Ethyl acetate RT 33 
3 Tetrahydrofurane  RT 54 
4 Nitromethane RT 38 
5 Tetrahydrofurane 50 42 
6 - 80 31 
aAll reactions were carried out in 24 hours with equal amounts of reactants. 
bIsolated yields. 
 
The Passerini reactions performed with N-benzyl, N
β
-Boc 
protected hydrazino acids (I) furnished corresponding Passerini 
products in 22-74 % yields (Table 2, products 1-12). It is known 
that the nature of an oxo-component (aldehyde/ketone) have 
significant impact on the outcome of the Passerini reactions.
 
Comparison of the Passerini reactions performed with p-NO2 
benzaldehyde (products 1, 2, 5 and 9), benzaldehyde (product 
6) and p-Cl benzaldehyde (10) revealed that aromatic 
aldehydes bearing electron withdrawing substituent furnished 
corresponding products in moderate to very good yields (36-63 
%), compared to unsubstituted aldehyde 6 (22 %), while no 
product was obtained with aldehyde bearing electron donating 
substituents. Reactions performed with aliphatic aldehyde 2-
methylpentanal (compounds 3, 4, 11 and 12) gave Passerini 
products in 21-74 % yields, indicating that reaction is also 
strongly influenced by the nature of acid and isocyano-
component. Finally, two ketones were used in the Passerini 
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reaction; product 7 was obtained with acetone in fair yield (42 
%), while acetophenone failed to give the expected product 8. 
Generally, lower yields were obtained with commercially 
available isocyanides (compounds 4, 9, 12) than with amino 
acid-derived ones. Also, amino acid side-chain group seems to 
have low impact on the reactivity in the Passerini reaction. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a Isolated yields are given in parentheses. Compounds were isolated as mixture of diastereoisomers. n.o. - not obtained 
Scheme 3 
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Next, we tested reactions with type II -hydrazino acids, 
namely leucine- and phenylalnine-related N-Boc, N
β
-Boc 
protected derivatives. Reactions were performed with p-NO2 
benzaldehyde, and 2-methylpentanal or acetone as oxo-
components in the presence of amino acid-derived 
isocyanides. Regardless oxo- and isocyano-components used, 
products 13-16 were obtained in low yields (10-24 %, Table 2). 
The utility of N-Cbz, N
β
-Boc protected hydrazino acids (type 
III) in the Passerini reaction was tested with the same set of 
oxo-compounds and various isocyanides, yielding hydrazino 
depsipeptides 17-24 (Table 2).   Passerini products with type III 
hydrazino acids are obtained in generally higher yields than 
with type II hydrazino acids (11-55 %). It is interesting to note, 
that two products isolated in highest yield, 18 and 21, are 
assembled of all three different components.  
Finally, the success of the protocol prompted us to test its 
scope with N
β
-Boc protected hydrazino proline. Because of the 
low reactivity of ketones observed in previous reactions, 
Passerini reactions were performed only with aldehydes. The 
corresponding products were isolated in low yields (25-28, 
Table 3), with the exception of p-NO2 benzaldehyde/cyclohexyl 
isocyanide combination which yielded the Passerini product 26 
in 55 % yield.  
Table 3. Scope of the protocol for the synthesis of hydrazino proline-related 
depsipeptides.a 
 
 
 
a Isolated yields are given in parentheses. Compounds were isolated as mixture of 
diastereoisomers. 
Comparison of obtained results revealed that efficiency of 
hydrazino acids in the Passerini reaction decreases in line: type 
I > type III > type II. The best examples are Passerini products 
11 (74 %) - 21 (54 %) - 14 (24 %) and also 1 (54 %) - 17 (11 %) - 
13 (17 %), where type II hydrazino acid afforded Passerini 
product is slightly better yield than type III hydrazino acid, but 
type I hydrazino acid-related Passerini product is obtained in 
by far better yield. Possible explanation for such outcome can 
be find in steric hindrance of Cbz and especially Boc group at 
the N atom, but also different nature of substituent; N-benzyl 
vs urethane type of bond. To investigate the disparity in a yield 
of products obtained by different hydrazino acids, we decided 
to get insight into reaction mechanism. An extensive research 
has been devoted to elucidate the mechanism of the Passerini 
reaction,
14c,17b,26
 including the theoretical approach by DFT 
methods in a paper of Maeda et al.
27
 Using the simplest set of 
reactants (formaldehyde, methyl isocyanide and formic acid) 
and calculating energies of all possible stationary points for the 
reaction at M0628/6-31G(d,p) + ZPE level of theory,
28
 it was 
found that the most productive mechanism in gas phase 
consists of seven steps: formation of H-bonded cluster 
between acid and aldehyde (1), followed by reaction with 
isocyanide (2) that results in occurrence of imidate (3). Imidate 
then forms H-bonded cluster with additional molecule of acid 
that serves as a catalyst (4), enabling rearrangement of this 
cluster with imidate to dioxolane intermediate (5) stabilized by 
H-bonds with additional acid molecule. Conformational change 
of H-bonded dioxolane-acid cluster (6) is necessary to allow 
the last step - Mumm rearrangement which results in the final 
product. The described mechanism is shown in Scheme 3, with 
acid counterpart represented as -hydrazino acid. 
Maeda et al. found that the rate-determining step is the 
rearrangement of the H-bonded imidate-acid cluster into the 
dioxolane-acid cluster (step 5, framed on Scheme 3).
27
 The 
calculated activation energy needed for this process was 51.8 
kJ mol
-1
 (at M06/6-31+G(d,p) + ZPE level of theory) with formic 
acid, formaldehyde and methyl isocyanide as reactants. 
Implicit model of solvation (PCM-M06/6-31+G(d,p)) in 
dichloromethane was used to estimate the influence of solvent 
to the energy profile of the reaction. The solvent effect was 
very mild, lowering energy barrier of the rate-determining step 
to 49.8 kJ mol
-1
. In more recent work by Ramozzi and 
Morokuma, the influence of solvent to the mechanism is 
additionally studied by DFT.
29
 It was found that in aprotic 
solvents, the stable nitrilium intermediate could be formed 
before the occurrence of imidate intermediate. The formation 
of nitrilium is also catalysed by additional molecule of acid, 
which means that in aprotic solvent the second (catalytic) 
molecule of acid enters the mechanism earlier than in the gas 
phase. The reaction then proceeds into the formation of 
imidate and rearrangements that lead to the final product.
28
 It 
is important to note that in this revised mechanism in aprotic 
solvents, the rate-determining step still remains the same: the 
transformation of imidate into dioxalane intermediate.  
We used DFT approach to calculate the kinetics and 
thermodynamic equilibrium of the rate-determining step of 
the Passerini reaction, with some of the reactants used in our 
work (Scheme 4). The results of computational modeling of the 
rate-determining step of the Passerini reaction were compared 
for two products with profound difference in yield, 11 (74 %), 
and 14 (24 %), Table 2. Two products differentiate only in -
hydrazino acid used in the synthesis, N-benzyl, N-Boc 
protected hydrazino phenylanine (type I) for 11 and N-Boc, 
N-Boc protected hydrazino phenylanine (type II) for 14. Since 
the only difference between these two sets of reactants was 
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the protective group on N atom of hydrazino phenylalanine 
(R
1
, Scheme 3 and Scheme 4), we estimated that it is safe to 
employ smaller model molecules as carbonyl species and 
isocyanide, for the sake of computational feasibility. 
Specifically, instead of 2-methylpentanal the formaldehyde 
was used, and methyl isocyanide was utilized in place of 2-
isocyano-3-methyl-methylbutanoate. One additional 
simplification was the replacement of the protective group on 
N atom of hydrazino acid; tert-butyloxycarbonyl (Boc) by 
methoxycarbonyl group (Moc), as shown in Scheme 4. 
 
 
 
Scheme 3 
 
Geometries of all stationary points (two minima and 
transition state) were optimized at the M06-2X28/6-31+G(d,p) 
level of theory. Vibrational analysis was performed to confirm 
the nature of each stationary point (NImag = 0 for minima and 
NImag = 1 for transition structure) and, in case of transition 
state, the single imaginary mode was confirmed to correspond 
to the reaction path that connects two minima. All energies 
were corrected for zero point vibrational energy (ZPE). 
Additionally, to be able to compare our results with those 
obtained by Maeda et al.
27
 we had to calculate the same 
process using Maeda’s reactants at the same level of theory 
applied in our work. Results were presented in Table 4. 
Calculated activation energies for the modelled reaction step 
are almost the same for all three analysed systems, as well as 
the thermodynamical equilibria between the two minima. 
Obviously, the disparity in product yield is not consequence of 
a different kinetics for this critical step of a reaction. 
However, if hidrazino acids are used instead of formic acid, 
imidate-acid cluster (Scheme 4) may undergo conformational 
changes that induce formation of alternative H-bonds between 
additional acid molecule (which serves as a catalyst for this 
reaction step) and the claster. Alternative H-bonds stabilize 
these non-productive conformations of cluster with imidate, 
so the reaction step from Scheme 4 cannot occur, and reaction 
does not proceed. Structures of productive conformations of 
imidate-acid cluster are shown in Figure 1, for N-benzyl, N-
Moc protected hydrazino phenylanine (left) and N-Boc, N-
Moc protected hydrazino phenylanine (right).  
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Scheme 4 
 
 
Table 4. Energy profile of reaction step presented in Scheme 4, calculated at M06-2X/6-
31+G(d,p) + ZPEM06-2X/6-31+G(d,p) level of theory (in kJ mol-1). First minima formed 
by clustering imidate and hydrazino acid is taken as a reference point 
 
 Imidate-acid 
cluster 
TS Dioxolan-acid 
cluster 
R1 = Bn 0 35.2 –13.1 
R1 = Boc 0 33.0 –18.2 
Maeda’s 
reactants27 
0 37.3 –17.6 
 
Non-productive conformers of imidate-acid cluster are 
schematically also presented in Figure 1. Two types of non-
productive conformers of imidate cluster are identified when 
hidrazino acid with R
1
 = benzyl is used, while three non-
productive conformations of imidate cluster are possible for 
the hidrazino acid with R
1
 = Boc. This third conformer is result 
of H-bond formation between the carbonyl oxygen on Boc and 
hydrogen from carboxylic group of acid. Obviously, in system 
when benzyl group is present instead of Boc at N atom, this 
additional H-bond cannot occur.    
To rationalize a difference in yield for Passerini reaction 
when using hydrazino acid with R
1
 = benzyl and R
1
 = Boc, 
respectively, we compared thermodynamical stability of non-
productive conformers with productive imidate cluster, for 
systems containing former and latter acid. Results are shown 
in Table 5. It turned out that non-productive minima for 
hidrazino acid where R
1
 = benzyl are only slightly more stable 
when compared to the productive conformation of imidate 
cluster (~10 kJ mol
-1
). Given that the whole reaction is 
relatively fast, that means that only small part of reactants 
finish in non-productive conformations. On the other side, two 
of three existing non-productive minima for system with R
1
 = 
Boc show significant stability when compared with productive 
conformation of imidate cluster (~50-60 kJ mol
-1
). The 
occurrence of very stable non-productive conformations of 
imidate cluster implies that the rearrangement of imidate to 
dioxolan which leads to the final product is then impeded. The 
data from Table 2 indicate that all products with R
1
 = Boc come 
with relatively low yield, in a range from 10 to 24 % 
(compounds 13-16), which may be rationalized in a same way 
as in case of the compound 14. 
 
 
 
 
Fig. 1 Schematic representation of productive and non-productive conformations of 
imidate-acid cluster with N-benzyl, N-Moc protected hydrazino phenylanine (left) and 
N-Boc, N-Moc protected hydrazino phenylanine (right). For the sake of simplicity, the 
structure of additional hydrazino acid is presented in abbreviated form, whereas the 
structure of the acid molecule covalently bound to the isocyanide and aldehyde is 
explicitly drawn. 
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Table 5. Energies of non-productive conformers of imidate cluster compared with 
energies of productive conformation for reactions when hydrazino acid with R1 = benzyl 
and R1 = Boc are used (in kJ mol-1), calculated at M06-2X/6-31+G(d,p) + ZPEM06-2X/6-
31+G(d,p) level of theory. 
  productive non-
productive 
1 
non-
productive 
2 
non-
productive 
3 
R1 = 
Bn 
 0 
–11.9 
–10.2 non-
existent 
R1 = 
Boc 
 0 –6.4 –50.5 –61.3 
 
Presence of additional functionalities in MCR products 
offers diverse post-condensation modifications affording new, 
structurally advanced scaffolds. Passerini-amine deprotection-
acyl migration (PADAM) is the most exploited post-Passerini 
protocol used for conversion of depsipeptides into -
oxoamides, structural motifs found in natural products and 
synthetic anticancer compounds and protease 
inhibitors.
15b,17b,26,30,31
  Next, diverse protocols were developed 
toward medium-sized cyclic and macrocyclic compounds, 
including ring-closing metathesis (RCM), macrolactonizations, 
click chemistry approaches and MCR-based cyclization.
15b
 In 
our particular case, transformation of linear hydrazino 
depsipeptides into their cyclic analogous would be attractive 
additional benefit of new peptidomimetic structures. As a 
proof-of-principle, we chose N-benzyl, N
β
-Boc-protected 
derivative 1 bearing methyl ester group at C-terminal position. 
Two-step deprotection procedure, base conditions for the 
removal of ester group followed by acid-promoted Boc 
cleavage, yielded unprotected hydrazino depsipeptide that 
was subjected to intramolecular cyclization in the presence of 
HATU coupling reagent, under pseudo-diluted conditions 
(Scheme 5). After HPLC purification cyclic hydrazino 
depsipeptide 29 was isolated in 15 % yield.  
 
 
Scheme 5 
Recently, a decarboxylative multicomponent reactions of α-
amino acid (proline) with various aldehydes and isocyanides 
yielding N-substituted proline amides were performed under 
metal-free conditions.
32
 Reaction is based on thermal 
decarboxylation of in-situ formed imine to form azomethine 
ylide, which undergoes nucleophilic insertion of isocyanide, 
followed by hydrolysis to furnish N-substituted proline amides. 
We speculated that in a similar manner, N-unsubstituted 
hydrazino acids could yield N-substituted amides. Therefore, 
a test reaction was performed under conditions found optimal 
for the decarboxylative multicomponent coupling with 
proline.
33
 A reaction of N
β
-Boc-protected hydrazino-L-
phenylalanine, p-nitro benzaldehyde and cyclohexyl isocyanide 
gave cyclohexyl amide of the N-substituted hydrazino acid 30 
(Scheme 6) in 20 % yield.  
 
 
Scheme 6 
 
Therefore, this procedure could be used for the synthesis 
of various N-substituted derivatives of hydrazino acids, but 
further development requires optimization of decarboxylative 
multicomponent reaction for hydrazino acids. Finally, N-
unsubstituted hydrazino acids can be exploited as bifunctional 
reagents in MCRs. While reaction performed under reaction 
conditions optimized for Passerini reaction gave no product, 
the same reactants in methanol after 24 h yielded Ugi-type of 
highly branched N-substituted hydrazino derivative 31 in 25 % 
yield (Scheme 6). So, our current efforts are directed toward 
further exploring the utility of hydrazino acids in other MCRs. 
Also, based on here proved methodology, we plan to develop 
a focused library of hydrazino depsipeptides, to probe 
interactions with nucleic acids and proteins. 
Conclusions 
We have developed methodology for the synthesis of new 
class of peptidomimetics  hydrazino depsipeptides, by 
multicomponent reaction of an -hydrazino acid, an aldehyde 
or ketone and an isocyanide component. -Hydrazino acids 
bearing different protecting groups at N were used to allow 
further specific modification of Passerini products. N-benzyl, 
N
β
-Boc protected hydrazino acids gave hydrazino 
depsipeptides in considerably better yields then their N-Boc 
and N-Cbz-protecting analogues. This finding was rationalized 
by DFT calculations showing that significant stability of two 
non-productive conformations of imidate intermediate in the 
rate-determining step of the reaction hinders rearrangement 
into dioxolan intermediate which leads to the Passerini 
product. 
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General Method 
All experiments were monitored by analytical thin layer 
chromatography (TLC) performed on Merck Kieselgel 60 F254 
0.25 mm precoated aluminium plates. After elution, plate was 
visualized under UV illumination at 254 nm for UV active 
materials. Further visualization was achieved by staining with 
ammonium molybdate and charring on a hot plate. Flash 
column chromatography was performed on silica gel (Merck, 
40−63 μm particle size) by standard techniques eluting with 
solvents as indicated. 
1
H NMR and 
13
C NMR spectra were 
recorded on Bruker Avance 600 MHz and 300 MHz 
spectrometers, operating at 150.92 or 75.47 MHz for 
13
C and 
600.13 or 300.13 MHz for 
1
H nuclei. Chemical shifts are quoted 
in ppm, and tetramethylsilane (TMS) was used as internal 
standard. Spectra were acquired at 298 K. Mass spectrometry 
measurements were performed on a triple quadrupole mass 
spectrometer, operating in a positive electrospray ionization 
(ESI) mode. High resolution mass spectrometry (HRMS) was 
performed on a nanoUPLC-ESI-qTOF in positive and negative 
mode. Racemic amino acid-derived isocyanides were prepared 
according to procedure published by Zhu and Danishesky.
34 
General Procedure 
To a glass vial containing 1 M solution of oxo-compound (0.11 
mmol) in THF under nitrogen were added N, N
β
-protected 
hydrazino acid (0.11 mmol) and the isocyanide (0.11 mmol). 
With all reactants added, the solution was allowed to stir for 
either 24 h in reactions with aldehydes or 48 h in reactions 
with ketones. The reactions were concentrated under reduced 
pressure and reaction mixtures were purified by flash column 
chromatography using petrol ether/ethyl acetate 2:1. Products 
were isolated and characterized as mixture of diastereisomers. 
tert-butyl 2-benzyl-2-((2S)-1-(2-((1-methoxy-1-oxo-3-
phenylpropan-2-yl)amino)-1-(4-nitrophenyl)-2-oxoethoxy)-4-
methyl-1-oxopentan-2-yl)hydrazine-1-carboxylate (1) Yield: 
54 % (40 mg); yellow oil;  Rf = 0.5 (petrol ether/ethyl acetate 
2:1, v/v); 
1
H NMR (CDCl3): δ 0.71–0.91 (m, 6H),  1.26-1.58 (m, 
12H), 3.15-3.25 (m, 3H), 3.72-3.81 (m, 2H), 3.83 (s, 3H), 4.75-
4.79 (m, 1H),  6.05-6.16 (m, 1H), 7.27-7.40 (m, 10H), 8.07 (d, J 
= 8.7 Hz, 2H), 8.18-8.25 (m, 2H), 8.39 (d, J = 8.6 Hz, 2H). 
13
C 
NMR (CDCl3): δ 20.4, 21.4, 21.5, 22.0, 22.30, 23.9, 24.0, 24.3, 
27.5, 27.7, 38.4, 38.5, 40.8, 41.1, 41.3, 50.2, 51.8, 52.7, 54.0, 
54.6, 60.1, 75.7, 76.3, 81.2, 127.0, 127.1, 127.4, 127.9, 128.2, 
128.3, 128.5, 128.7, 128.9, 129.1, 129.3, 129.4, 136.5, 159.8, 
167.1, 171.7. MS (ESI+): m/z = 677.6. HRMS: Calcd. for 
C36H45N4O9 [M+H]
+
 677.3187; found 677.3184. 
tert-butyl 2-benzyl-2-((2S)-1-(2-(1-methoxy-1-oxo-3-
phenylpropan-2-ylamino)-1-(4-nitrophenyl)-2-oxoethoxy)-3-
methyl-1-oxobutan-2-yl)hydrazinecarboxylate (2). Yield: 63 % 
(37 mg); yellow oil; Rf = 0.6 petrol ether/ethyl acetate 2:1, v/v). 
1
H NMR (CDCl3): δ 0. 71-0.89 (m, 3H), 1.01-1.13 (m, 3H), 1.32-
1.46 (m, 9H), 1.98-2.14 (m, 1H), 3.00-3.27 (m, 3H), 3.72-4.10 
(m, 5H), 4.88–4.98 (m, 1H), 6.04-6.19 (m, 1H), 6.69-6.80 (m, 
2H), 7.05-768 (m, 12H), 8.16-8.25 (m, 2H). 
13
C NMR (CDCl3): δ 
18.4, 18.8, 19.1, 27.1, 27.7, 28.1, 29.2, 34.9, 36.0, 52.0, 52.1, 
52.3, 52.5, 52.6, 52.8, 66.8, 70.7, 73.8, 74.0, 80.0, 123.4, 123.8, 
126.8, 127.1, 127.4, 127.8, 128.2, 128.4, 128.5, 128.6, 128.9, 
129.2, 129.3, 129.4, 130.0, 134.7, 136.0, 136.3, 141.4, 147.8, 
166.0, 170.8, 170.9.  MS (ESI+): m/z = 663.5. HRMS: Calcd. for 
C35H43N4O9 [M+H]
+
 663.3030; Found 663.3036. 
tert-butyl 2-benzyl-2-((2R)-1-(1-(1-methoxy-3-methyl-1-
oxobutan-2-ylamino)-3-methyl-1-oxohexan-2-yloxy)-3-
methyl-1-oxobutan-2-yl)hydrazinecarboxylate (3). Yield: 21 % 
(12 mg); yellow oil; Rf= 0.7 (petrol ether/ethyl acetate 2:1, v/v). 
1
H NMR (CDCl3): δ 0.91-1.05 (m, 18H), 1.13-1.40 (m, 13H), 
2.05-2.35 (m, 3H), 3.10-3.45 (m, 1H), 3.58-4.05 (m, 5H), 4.55-
4.70 (m, 1H), 4.80-5.20 (m, 1H), 7.27-7.68 (m, 7H). 
13
C NMR 
(CDCl3): δ 13.4, 13.5, 13.6, 13.9, 14.1, 14.5, 14.6, 16.2, 16.6, 
17.3, 17.5, 17.8, 19.0, 19.2, 19.7, 19.9, 27.6, 27.8, 28.1, 28.2, 
30.8, 31.4, 32.6, 36.0, 52.2, 52.4, 57.1, 57.3, 65.7, 78.3, 78.9, 
87.2, 127.0, 127.6, 128.5, 128.9, 129.2, 129.4, 137.0, 154.9, 
156.6, 171.9, 177.0, 178.2. MS (ESI+): m/z = 564.4. HRMS: 
Calcd. for C30H50N3O7 [M+H]
+
 564.3649; Found 564,3649. 
tert-butyl 2-benzyl-2-((2R)-1-(1-(tert-butylamino)-3-methyl-1-
oxohexan-2-yloxy)-3-methyl-1-oxobutan-2-
yl)hydrazinecarboxylate (4). Yield: 29 % (18 mg); yellow oil; Rf 
= 0.75 (petrol ether/ethyl acetate 2:1, v/v). 
1
H NMR (CDCl3): δ 
0.88-0.94 (m, 15H), 1.30-1.37 (m, 19H), 2.05-2.10 (m, 1H), 
2.48-2.52 (m, 1H), 3.15-3.35 (m, 1H), 3.75-4.15 (m, 2H), 4.75-
5.10 (m, 1H), 5.65-5.75 (br s, 1H), 6.75-7.75 (m, 7H). 
13
C NMR 
(CDCl3): δ 13.6, 16.3, 19.3, 19.9, 27.7, 28.16, 28.22, 33.6, 34.9, 
35.5, 38.1, 65.7, 66.2, 68.3, 78.3, 78.9, 87.4, 127.0, 127.7, 
131.4, 147.7, 161.9, 170.7, 172.2. MS (ESI+): m/z = 506.4. ESI-
HRMS: Calcd. for C28H48N3O5 [M+H]
+
 506.3594; Found 
506.3594. 
tert-butyl 2-benzyl-2-((2S)-1-(2-(1-methoxy-1-oxo-3-
phenylpropan-2-ylamino)-1-(4-nitrophenyl)-2-oxoethoxy)-1-
oxopropan-2-yl)hydrazinecarboxylate (5) Yield: 59 % (41 mg); 
yellow oil; Rf= 0.45 (petrol ether/ethyl acetate 2:1, v/v); 
1
H 
NMR (CDCl3): δ 1.32-1.41 (m, 12H), 3.03-3.30 (m, 2H), 3.68-
3.80 (m, 4H), 3.85-4.05 (m, 2H), 4.79-4.94 (m, 1H), 6.13-6.20 
(m, 1H), 6.25-6.40 (m, 1H), 6.80-7.60 (m, 13H), 8.14-8.23 (m, 
2H). 
13
C NMR (CDCl3): δ 18.4, 18.8, 19.1, 19.4, 27.1, 27.7, 28.2, 
29.2, 34.9, 36.7, 37.0, 38.4, 52.0, 52.1, 52.3, 52.5, 52.6, 52.8, 
66.8, 70.7, 73.8, 74.0, 79.4, 123.4, 123.8, 126.8, 127.1, 127.2, 
127.8, 128.1, 128.3, 128.4, 128.6, 128.9, 129.3, 129.2, 129.4, 
134.7, 136.0, 136.3, 141.3, 147.8, 166.0, 171.6, 171.9. MS 
(ESI+): m/z = 635.4. HRMS: Calcd. for C33H39N4O9 [M+H]
+
 
635.2717; found 635.2716.  
tert-butyl 2-benzyl-2-((2S)-1-(2-(1-methoxy-4-methyl-1-
oxopentan-2-ylamino)-2-oxo-1-phenylethoxy)-4-methyl-1-
oxopentan-2-yl)hydrazinecarboxylate (6). Yield: 22 % (17 mg); 
yellow oil; Rf = 0.6 (petrol ether/ethyl acetate 2:1, v/v). 
1
H NMR 
(CDCl3): δ 0.85-0.98 (m, 12H), 1.49-1.57 (m, 11H), 1.66-1.78 
(m, 4H), 3.58-3.80 (m, 5H), 3.84-4.20 (m, 2H), 4.55-4.67 (m, 
1H), 5.25-5.55 (m, 1H), 6.10-6.40 (m, 1H), 7.30-8.20 (m, 12H). 
13
C NMR (CDCl3): δ 21.1, 22.2, 24.4, 27.5, 27.7, 27.8, 29.2, 36.1, 
38.2, 41.1, 41.3, 50.2, 50.3, 51.9, 52.2, 53.0, 54.0, 58.6, 60.1, 
62.6, 75.0, 75.36, 75.41, 79.2, 80.9, 126.8, 127.0, 127.2, 127.7, 
128.1, 128.2, 128.4, 128.5, 128.8, 129.1, 129.3, 129.8, 133.1, 
133.2, 137.9, 140.7, 164.3, 164.4, 167.3. MS (ESI+): m/z = 
598.5. HRMS: Calcd. for C33H48N3O7 [M+H]
+
 598.3492; found 
598.3486. 
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tert-butyl 2-benzyl-2-((2S)-1-(1-(1-methoxy-4-methyl-1-
oxopentan-2-ylamino)-2-methyl-1-oxopropan-2-yloxy)-4-
methyl-1-oxopentan-2-yl)hydrazinecarboxylate (7). Yield: 42 
% (30 mg); yellow oil; Rf = 0.7 (petrol ether/ethyl acetate 2:1, 
v/v). 
1
H NMR (CDCl3): δ 0.96-1.01 (m, 12H), 1.32-1.43 (m, 5H), 
1.50-1.63 (m, 12H), 1.67-1.77 (m, 2H), 1.80-1.95 (m, 2H), 3.74 
(s, 3H), 3.78 (s, 2H), 3.85-4.10 (m, 1H), 4.20-4.32, m(1H), 4.55-
4.80 (m, 1H), 7.30–7.45 (m, 7H). 
13
C NMR (CDCl3): δ 20.4, 21.4, 
21.5, 22.0, 22.4, 24.0, 24.3, 27.5, 27.7, 27.8, 38.4, 38.5, 40.8, 
41.1, 41.3, 48.8, 50.2, 50.3, 51.8, 52.3, 52.7, 54.1, 54.6, 58.6, 
60.1, 67.1, 75.7, 81.3, 127.0, 127.4, 127.7, 127.8, 128.0, 128.5, 
129.0, 129.2, 131.1, 136.6, 160.0, 168.8, 171.8. MS (ESI+): m/z 
= 550.6. HRMS: Calcd. for C29H48N3O7 [M+H]
+
 550.3492, found 
550.3491. 
tert-butyl 2-benzyl-2-((2S)-1-(2-(cyclohexylamino)-1-(4-
nitrophenyl)-2-oxoethoxy)-1-oxo-3-phenylpropan-2-
yl)hydrazinecarboxylate (9). Yield: 36 % (25 mg); yellow oil; Rf= 
0.4 (petrol ether/ethyl acetate 2:1, v/v). 
1
H NMR (CDCl3): δ 
1.27-1.60 (m, 19H), 2.95-3.25 (m, 2H), 3.55-4.15 (m, 4H), 4.80–
5.20 (m, 1H), 5.85-6.18 (m, 1H), 7.20-7.35 (m, 6H), 8.05-8.11 
(m, 4H), 8.36-8.44 (m, 5H). 
13
C NMR (75 MHz, CDCl3) δ 24.3, 
24.8, 24.9, 27.5, 27.7, 29.2, 32.2, 32.3, 35.4, 48.3, 66.9, 74.2, 
74.3, 74.6, 83.0, 123.3, 123.8, 126.3, 127.3, 127.7, 127.8, 
127.9, 128.1, 128.3, 128.5, 128.6, 128.8, 129.3, 130.0, 133.6, 
139.4, 170.1, 170.2. MS (ESI+): m/z = 631.3. HRMS: Calcd. for 
C35H43N4O7 [M+H]
+
 631.3132; found 631.3134. 
tert-butyl 2-benzyl-2-((2S)-1-(1-(1-methoxy-3-methyl-1-
oxobutan-2-ylamino)-3-methyl-1-oxohexan-2-yloxy)-1-oxo-3-
phenylpropan-2-yl)hydrazinecarboxylate (11). Yield: 74 % (64 
mg;); yellow oil; Rf = 0.65 (petrol ether/ethyl acetate 2:1, v/v). 
1
H NMR (CDCl3): δ 0.92 (d, J = 6.9 Hz, 6H),  0.96 (d, J = 6.9 Hz, 
6H), 1.40-1.46 (m, 4H), 1.52 (s, 9H), 2.20-2.25 (m, 2H), 2.30-
2.35 (m, 3H), 3.70-3.73 (m, 5H), 4.23 (s, 3H), 4.53-4.61 (m, 1H), 
4.63-4.70 (m, 1H), 7.17-7.38 (m, 10H), 8.30 (br s, 1H), 8.92 (d, 
1H). 
13
C NMR (CDCl3): δ 16.8, 17.8, 17.9, 19.1, 19.4, 20.3, 28.1, 
28.3, 31.4, 31.5, 33.7, 34.0, 52.4, 53.3, 55.8, 56.7, 63.0, 63.1, 
78.2, 78.6, 83.9, 126.7, 127.6, 128.2, 128.3, 128.5, 128.9, 
129.3, 129.5, 129.8, 160.7, 167.0, 172.2. MS (ESI+): m/z = 
612.6. ESI-HRMS: Calcd. for C34H50N3O7 [M+H]
+
 612.3649; 
found 612.3646. 
tert-butyl 2-benzyl-2-((2S)-1-(1-(2-methoxy-2-
oxoethylamino)-3-methyl-1-oxohexan-2-yloxy)-1-oxo-3-
phenylpropan-2-yl)hydrazinecarboxylate (12). Yield: 32 % (26 
mg), yellow oil; Rf = 0.46 (petrol ether/ethyl acetate 2:1, v/v). 
1
H NMR (CDCl3): δ 0.84-0.91 (m, 6H), 1.30–1.50 (m, 13H), 3.10-
3.18 (m, 1H), 3.58-3.80 (m, 4H), 3.85-4.20 (m, 3H), 4.35-4.60 
(br s, 1H), 5.11-5.28 (m, 1H), 6.45-6.75 (m, 1H), 7.05-7.42 (m, 
8H), 7.45-8.15 (m, 3H). 
13
C NMR (CDCl3): δ 13.6, 13.8, 19.7, 
27.7, 28.2, 32.8, 35.1, 35.8, 40.4, 46.3, 52.3, 60.8, 78.1, 79.8, 
83.7, 127.8, 128.2, 128.4, 128.5, 128.8, 130.5, 133.2, 148.1, 
176.6, 178.5, 180.9. MS (ESI+): m/z = 570.3. ESI-HRMS: Calcd. 
for C31H44N3O7 [M+H]
+
 570.3179; found 570.3173. 
di-tert-butyl 1-((2S)-1-(2-(1-methoxy-1-oxo-3-phenylpropan-
2-ylamino)-1-(4-nitrophenyl)-2-oxoethoxy)-4-methyl-1-
oxopentan-2-yl)hydrazine-1,2-dicarboxylate (13). Yield: 17 % 
(13 mg); colorless oil; Rf = 0.45 (petrol ether/ethyl acetate 2:1, 
v/v). 
1
H NMR (CDCl3): δ 0.90-0.95 (m, 6H), 1.48-1.52 (m, 20H), 
1.73-1.85 (m, 2H), 3.02-3.19 (m, 3H), 3.71-3.79 (m, 3H), 4.75-
4.96 (m, 2H), 6.09-6.15 (br s, 1H), 7.15-7.27 (m, 7H), 7.55-7.63 
(br s, 1H), 8.12-8.25 (m, 2H). 
13
C NMR (CDCl3) δ 21.9, 23.1, 
24.7, 28.2, 28.3, 29.8, 37.3, 37.5, 39.1, 52.6, 53.4, 53.6, 75.3, 
82.5, 82.6, 123.9, 124.3, 127.3, 127.8, 128.1, 128.6, 129.2, 
129.7, 130.6, 148.2, 166.9, 171.4. MS (ESI+): m/z = 687.4. ESI-
HRMS: Calcd. for C34H47N4O11 [M+H]
+
 687.3241; found 
687.3237. 
di-tert-butyl 1-((2S)-1-(1-(1-methoxy-3-methyl-1-oxobutan-2-
ylamino)-3-methyl-1-oxohexan-2-yloxy)-1-oxo-3-
phenylpropan-2-yl)hydrazine-1,2-dicarboxylate (14). Yield: 24 
% (21 mg); colorless oil; Rf = 0.7 (petrol ether/ethyl acetate 2:1, 
v/v). 
1
H NMR (CDCl3): δ 0.85-0.98 (m, 8H), 1.01 (d, 3H), 1.12 (d, 
3H), 1.29-1.55 (m, 20H), 2.12-2.35 (m, 2H), 3.18-3.32 (m, 2H), 
3.82 (s, 3H), 4.17 (m, 1H), 4.35-4.55 (m, 1H), 5.02-5.16 (m, 1H), 
7.13–7.44 (m, 6H). 
13
C NMR (CDCl3): δ 13.6, 14.8, 16.2, 18.6, 
19.6, 27.5, 27.6, 29.2, 30.7, 34.2, 34.9, 51.4, 52.6, 56.7, 62.3, 
78.7, 126.2, 126.3, 128.0, 128.1, 129.0, 160.1, 166.4, 172.5. MS 
(ESI+): m/z = 622.5. ESI-HRMS: Calcd. for C32H52N3O9 [M+H]
+
 
622,3704; found 622,3694.  
di-tert-butyl 1-((2S)-1-(2-(2-methoxy-2-oxoethylamino)-1-(4-
nitrophenyl)-2-oxoethoxy)-1-oxo-3-phenylpropan-2-
yl)hydrazine-1,2-dicarboxylate (15). Yield: 23 % (20 mg); 
colorless oil; Rf = 0.2 (petrol ether/ethyl acetate 2:1, v/v). 
1
H 
NMR (CDCl3): δ 1.34-1.50 (m, 18H), 3.08-3.27 (m, 2H), 3.46 (s, 
3H), 3.69 (s, 2H), 3.97-4.12 (m, 1H), 6.02-6.18 (m, 1H), 7.02-
7.42 (m, 6H), 7.55-7.75 (br s, 1H), 8.02-8.45 (m, 4H). 
13
C NMR 
(CDCl3): δ 28.1, 29.7, 30.2, 40.7, 50.8, 52.1, 75.2, 75.5, 82.4, 
82.6, 123.5, 124.3, 126.6, 127.1, 128.6, 129.0, 129.3, 130.5, 
140.1, 142.4, 148.0, 167.8, 169.6, MS (ESI+): m/z = 631.2. ESI-
HRMS: Calcd. for C30H39N4O11 [M+H]
+
 631.2615; found 
631.2609. 
di-tert-butyl 1-((2S)-1-(1-(1-methoxy-4-methyl-1-oxopentan-
2-ylamino)-2-methyl-1-oxopropan-2-yloxy)-1-oxo-3-
phenylpropan-2-yl)hydrazine-1,2-dicarboxylate (16). Yield: 10 
% (8 mg); colorless oil; Rf = 0.42 (petrol ether/ethyl acetate 2:1, 
v/v). 
1
H NMR (CDCl3): δ 0.91-0.96 (m, 6H), 1.32-1.48 (m, 20H), 
1.57-1.66 (m, 7H), 3.05-3.19 (m, 2H), 3-55-3.69 (br s, 3H), 4.35-
4.73 (m, 2H), 7.20-7.35 (m, 7H). 
13
C NMR (CDCl3): δ 21.2, 22.1, 
22.4, 22.9, 24.3, 27.5, 27.6, 37.4, 50.0, 50.3, 51.2, 51.5, 81.4, 
82.2, 126.4, 127.3, 127.8, 128.3, 128.6, 129.0, 167.2, 173.0. MS 
(ESI+): m/z = 594.5. ESI-HRMS: Calcd. for C30H48N3O9 [M+H]
+
 
594.3391; found 594.3384. 
1-benzyl 2-tert-butyl 1-((2S)-1-(2-(1-methoxy-1-oxo-3-
phenylpropan-2-ylamino)-1-(4-nitrophenyl)-2-oxoethoxy)-4-
methyl-1-oxopentan-2-yl)hydrazine-1,2-dicarboxylate (17). 
Yield: 11 % (9 mg); colorless oil; Rf = 0.43 (petrol ether/ethyl 
acetate 2:1, v/v). 
1
H NMR (CDCl3): δ 0.80-0.98 (m, 6H), 1.50-
1.65 (br s, 20H), 3.01-3.29 (m, 2H), 3.55-3.75 (m, 3H), 4.65-4.79 
(m, 2H), 5.07-5.28 (m, 2H), 5.95-6.25 (m, 1H), 7.25-7.40 (m, 
12H), 7.75-8.40 (m, 4H). 
13
C NMR (CDCl3): δ 21.7, 23.0, 24.4, 
28.4, 35.3, 39.0, 53.6, 59.2, 65.6, 68.9, 72.3, 124.1, 124.5, 
127.1, 127.7, 129.4, 129.5, 129.7, 130.6, 131.1, 141.0, 156.9, 
169.1, 170.8, 171.5. MS (ESI+): m/z = 721.6. ESI-HRMS: Calcd. 
for C37H45N4O11 [M+H]
+ 
721.3085; found 721.3076. 
1-benzyl 2-tert-butyl 1-((2S)-1-(2-(cyclohexylamino)-1-(4-
nitrophenyl)-2-oxoethoxy)-4-methyl-1-oxopentan-2-
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yl)hydrazine-1,2-dicarboxylate (18). Yield: 55 % (39 mg); 
Colorless oil; Rf = 0.45 (petrol ether/ethyl acetate 2:1, v/v).
 1
H 
NMR (CDCl3) δ 0.75-2.15 (m, 26H), 3.76 (br s, 1H), 5.15-5.25 
(m, 1H), 6.95-6.20 (m, 1H), 7.29-7.33 (m, 5H), 7.55-7.63 (m, 
2H), 8.10-8.25 (m, 2H). 
13
C NMR (CDCl3) δ 22.9, 24.8 25.4, 28.0, 
29.4, 32.6, 32.8, 35.0, 48.7, 57.9, 65.4, 71.1, 85.3, 123.7, 127.0, 
127.7, 128.6, 130.5, 139.3, 140.1, 140.9, 150.2, 151.2, 169.2, 
170.6, 171.2 MS (ESI+): m/z = 641.2. ESI-HRMS: Calcd. for 
C33H45N4O9 [M+H]
+
 641.3187; found 641.3187. 
1-benzyl 2-tert-butyl 1-((2S)-1-(1-(cyclohexylamino)-3-methyl-
1-oxohexan-2-yloxy)-4-methyl-1-oxopentan-2-yl)hydrazine-
1,2-dicarboxylate (19). Yield: 27 % (29 mg); colorless oil; Rf = 
0.43 (petrol ether/ethyl acetate 2:1, v/v). 
1
H NMR (CDCl3): δ 
0.63-1.15 (m, 12H), 1.16-1.25 (m, 6H), 1.30-1.42 (m, 6H), 1.55-
1.62 (m, 3H), 1.65-1.75 (m, 4H), 1.80-1.90 (m, 3H), 3.70-3.85 
(m, 2H), 5.05-5.20 (m, 2H), 5.73 (m, 1H), 7.19-7.23 (m, 5H). 
13
C 
NMR (CDCl3): δ 13.6, 15.1, 19.6, 20.4, 24.3, 25.0, 27.5, 32.5, 
32.6, 33.1, 34.6, 34.7, 47.4, 68.0, 74.1, 76.4, 78.0, 127.8, 128.1, 
128.7, 142.1, 167.6, 168.0, 169.1, 169.2. MS (ESI+): m/z = 
590.6. HRMS: Calcd. for C32H52N3O7 [M+H]
+
 590.3805; found 
for 590.3805.  
1-benzyl 2-tert-butyl 1-((2S)-1-(1-(tert-butylamino)-3-methyl-
1-oxohexan-2-yloxy)-4-methyl-1-oxopentan-2-yl)hydrazine-
1,2-dicarboxylate (20). Yield: 32 % (20 mg); colorless oil; Rf = 
0.36 (petrol ether/ethyl acetate 2:1, v/v). 
1
H NMR (300 MHz, 
CDCl3) δ 0.79-1.85 (m, 25H), 4.60-4.75 (m, 3H), 5.21 (br s, 1H), 
7.25-7.42 (m, 7H). 
13
C NMR (CDCl3): δ 13.5, 13.6, 13.7, 14.5, 
14.6, 19.6, 24.0, 27.6, 28.1, 29.2, 34.6, 42.2, 61.3, 64.9, 67.8, 
80.6, 88.6, 127.9, 128.0, 128.1, 137.1, 153.8, 155.4, 169.4, 
172.3. MS (ESI+): m/z = 564.4. ESI-HRMS: Calcd. for C30H50N3O7 
[M+H]
+
 564.3649; found 564.3647. 
 
1-benzyl 2-tert-butyl 1-((2S)-1-(1-(1-methoxy-3-methyl-1-
oxobutan-2-ylamino)-3-methyl-1-oxohexan-2-yloxy)-1-oxo-3-
phenylpropan-2-yl)hydrazine-1,2-dicarboxylate (21). Yield: 54 
% (50 mg); colorless oil; Rf = 0.46 (petrol ether/ethyl acetate 
2:1, v/v). 
1
H NMR (CDCl3) δ 0.66-0.82 (m, 12H), 1.10–1.55 (m, 
13H), 1.84 (br s, 1H), 2.09 (br s, 1H), 3.12-3.30 (m, 2H), 3.53-
3.65 (m, 3H), 4.43 (br s, 1H), 4.68 (s, 2H), 5.12-5-25 (m, 2H), 
7.14-7.24 (m, 11H). 
13
C NMR (CDCl3) δ 14.0, 14.1, 15.3, 18.1, 
19.0, 20.1, 20.2, 28.0, 30.7, 34.9, 52.0, 57.2, 65.3, 68.5, 78.6, 
81.6, 127.0, 127.6, 128.0, 128.5, 128.6, 128.7, 135.6, 141.0, 
155.7, 156.0, 169.2, 169.8, 172.0. MS (ESI+): m/z = 656.4. ESI-
HRMS: Calcd. for C35H50N3O9 [M+H]
+
 656.3547; found 
656.3544.   
1-benzyl 2-tert-butyl 1-((2S)-1-(1-(tert-butylamino)-3-methyl-
1-oxohexan-2-yloxy)-1-oxo-3-phenylpropan-2-yl)hydrazine-
1,2-dicarboxylate (22). Yield: 43 % (28 mg); colorless oil; Rf = 
0.57 (petrol ether/ethyl acetate 2:1, v/v). 
 1
H NMR (CDCl3) δ 
0.77-0.88 (m, 4H), 1.20-1.50 (m, 20H), 1.55-1.85 (m, 5H), 3.03-
3.30 (m, 2H), 4.55-4.70 (m, 2H), 5.09-5.25 (m, 2H), 7.16-7.43 
(m, 12H). 
13
C NMR (CDCl3) δ 14.0, 14.1, 20.1, 28.5, 28.6, 29.7, 
34.9, 35.2, 35.7, 51.4, 65.3, 68.5, 82.1, 127.0, 127.6, 128.7, 
128.8, 140.9, 154.4, 155.2, 168.5, 169.2. MS (ESI+): m/z = 
598.5. ESI-HRMS: Calcd. for C33H48N3O7 [M+H]
+
 598.3492; 
found 598.3489. 
1-benzyl 2-tert-butyl 1-((2S)-1-(2-(2-methoxy-2-
oxoethylamino)-1-(4-nitrophenyl)-2-oxoethoxy)-1-oxo-3-
phenylpropan-2-yl)hydrazine-1,2-dicarboxylate (23). Yield: 32 
% (30 mg); colorless oil; Rf = 0.17 (petrol ether/ethyl acetate 
2:1, v/v).
 1
H NMR (CDCl3) δ 1.25-1.45 (s, 9H), 3.15-3.30 (m, 2H), 
3.55-4.18 (m, 6H), 5.12-5.25 (m, 2H), 6.04-6.20 (br s, 1H), 7.10-
7.60 (m, 10H), 7.50-7.60 (m, 2H), 8.00-8.20 (m, 2H). 
13
C NMR 
(75 MHz, CDCl3) δ 28.1, 29.8, 40.9, 52.3, 67.0, 68.6, 73.7, 82.6, 
123.6, 123.7, 126.9, 127.0, 127.3, 127.8, 128.1, 128.6, 128.7, 
128.8, 129.1, 129.2,  136.3, 136.7, 142.2, 146.8, 148.2, 155.1, 
167.7, 169.7, 169.9, 171.2. MS (ESI+): m/z = 665.3. ESI-HRMS: 
Calcd. for C33H37N4O11 [M+H]
+
 665.2459; found for 665.2458. 
(2S)-2-(1-methoxy-4-methyl-1-oxopentan-2-ylamino)-1-(4-
nitrophenyl)-2-oxoethyl 1-(tert-butoxycarbonylamino) 
pyrrolidine-2-carboxylate (25). Yield: 16 % (11 mg); yellow oil; 
Rf = 0.47 (petrol ether/ethyl acetate 2:1, v/v). 
1
H NMR (CDCl3): 
δ 0.88–0.97 (m, 6H), 1.49 (s, 9H), 1.62-1.78 (m, 4H), 1.82-2.10 
(m, 4H), 3.75-2.95 (m, 1H), 3.25-3.80 (m, 1H), 3.67-3.75 (m, 
3H), 3.80-3.92 (m, 1H), 4.60-4.71 (m, 1H), 5.35-5.55 (m,. 2H), 
6.19 (s, 1H),7.20-7.45 (m, 2H),  7.64-7.74 (m, 2H), 8.12-8.45 (m, 
3H). 
13
C NMR (CDCl3): δ 21.6, 21.8, 22.7, 22.8, 22.9, 24.2, 24.7, 
24.9, 28.2, 28.4, 40.6, 40.8, 40.9, 45.8, 46.7, 50.7, 52.3, 52.5, 
64.0, 74.6, 74.9, 78.0, 78.3, 78.6, 81.3, 81.5, 123.8, 124.3, 
127.9, 129.0, 130.5, 142.4, 148.2, 155.6, 167.1, 171.7, 172.6. 
MS (ESI+): m/z = 422.2. ESI-HRMS: Calcd for C20H26N3O7 [M-
BocNH-H]
-
 420.1771; found 420.1778.  
(2S)-2-(cyclohexylamino)-1-(4-nitrophenyl)-2-oxoethyl 1-(tert-
butoxycarbonylamino) pyrrolidine-2-carboxylate (26). Yield: 
54 % (48 mg); orange oil; Rf = 0.4 (petrol ether/ethyl acetate 
2:1, v/v). 
1
H NMR (CDCl3) δ 1.20-1.40 (m, 5H), 1.52-1.96 (m, 
20H), 2.70-2.78 (m, 1H), 3.16-3.29 (m, 1H), 3.74-3.88 (m, 2H), 
5.30-5.70 (m, 2H), 6.13 (s, 1H), 6.92-7.05 (m, 1H), 7.66-7.72 (m, 
2H), 8.20-8.25 (m, 2H). 
13
C NMR (CDCl3): δ 24.3, 24.7, 25.1, 
25.4, 27.5, 28.2, 28.3, 32.7, 32.8, 45.8, 48.6, 48.7, 63.1, 64.1, 
74.8, 75.1, 78.0, 81.4, 81.5, 123.7, 123.8, 124.3, 128.0, 128.7, 
130.5, 142.9, 148.1, 155.7, 155.8, 166.0, 166.1, 170.6, 171.4. 
MS (ESI+): m/z = 376.3. ESI-HRMS: Calcd. for C24H33N4O7 [M-H]
-
 
489.2349; found 489.2336. 
(2S)-2-(tert-butylamino)-1-(4-nitrophenyl)-2-oxoethyl 1-(tert-
butoxycarbonylamino) pyrrolidine-2-carboxylate (27). Yield: 
20 % (12 mg); colorless oil; Rf = 0.45 (petrol ether/ethyl acetate 
2:1, v/v). 
1
H NMR (CDCl3): δ 1.39 (s, 9H), 1.49 (s, 9H), 1.96-2.15 
(m, 4H), 2.88-2.95 (br s, 1H), 3-20-3.28 (br s, 1H), 3.93-4.05 (m, 
1H), 5.45-5.57 (m, 2H), 6.04 (s, 1H), 6.55 (br s, 1H), 7.64 (d, J = 
8.7 Hz, 2H), 8.21 (d, J = 8.8 Hz, 2H). 
13
C NMR (CDCl3) δ 24.7, 
24.9, 28.2, 28.5, 28.6, 28.7, 29.7, 46.2, 46.8, 52.0, 64.3, 64.5, 
74.7, 75.3, 81.2, 81.3, 123.8, 124.1, 124.3, 127.1, 128.0, 128.4, 
130.5, 143.0, 143.1, 148.0, 155.5, 166.1, 166.2, 171.1, 171.5. 
MS (ESI+): m/z = 350.1. ESI-HRMS: Calcd. for C17H22N3O5 [M-
BocNH-H]
-
 348.1559; found 348.1559. 
(2S)-1-(2-methoxy-2-oxoethylamino)-3-methyl-1-oxohexan-2-
yl 1-(tert-butoxycarbonylamino) pyrrolidine-2-carboxylate 
(28). Yield: 13 % (12 mg); colorless oil; Rf = 0.3 (petrol 
ether/ethyl acetate 2:1, v/v). 
1
H NMR (CDCl3): δ 0.87-0.90 (m, 
3H), 0.90-0.98 (m, 3H), 1.46-1.50 (m, 11H), 1.8-2.20 (m, 6H), 
2.65-2.80 (m, 1H), 3.20-3.30 (m, 1H), 3.80-4.25 (m, 3H), 
5.25.5.33 (m, 1H), 5.75-5.80 (m, 1H), 7.25-7.50 (br s, 1H). 
13
C 
NMR (CDCl3) δ 14.1, 14.2, 15.5, 15.8, 20.1, 20.2, 20.3, 23.3, 
24.3, 28.1, 28.2, 28.5, 34.9, 35.1, 35.5, 25.6,  40.7, 46.8,  52.0, 
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52.1, 52.5, 63.5, 63.763.8, 63.9, 67.0, 78.2, 78.3, 78.4, 81.3, 
81.4, 81.5, 155.7, 155.8, 156.1, 156.2, 160.9, 169.6, 169.7, 
169.9, 170.1, 170.3, 171.6, 171.8, 172.2. ESI-HRMS: Calcd. for 
C20H34N3O7 [M-H]
-
 428.2397; found 428.2389. 
Synthesis of (3S)-4,7-dibenzyl-3-isobutyl-10-(4-nitrophenyl)-
1,4,5,8-oxatriazecane-2,6,9-trione (29)  
Passerini product 5 (40 mg; 0.063 mmol) was dissolved in 
MeOH and 1M NaOH (126 µL, 0.13 mmol) was added. Reaction 
was stirred under reflux and followed by TLC (petrol 
ether/ethyl acetate 2:1, v/v). After 1 h, solvent was 
evaporated, residue dissolved in water, pH adjusted to 3 by 
citric acid and product extracted with EtOAc. Crude product 
was dissolved in TFA-H2O (9:1, v/v, 1 mL), reaction was stirred 
at room temperature 1 h and then product precipitated with 
di-isopropyl ether. Crude product (22 mg, 0.042 mmol) and 
TEA (6 µL; 0.042 mmol) were dissolved in dry DMF (12 mL), 
and the solution was added dropwise via a syringe pump (flow 
rate 0.8 mL/h) into the solution of HATU (36 mg; 0.092 mmol) 
and TEA (6 µL; 0.042 mmol) in dry DMF (2 mL). The solvent was 
diluted with water, product extracted with ether, washed with 
brine and water and purified by HPLC. Yield: 15 % (4.5 mg); 
colourless oil; TR = 26.7 min (C-18 RP HPLC column (150 × 4.5 
mm, ID 5 μm), liner gradient from 30 % MeOH to 90 % MeOH 
in 60 min; λ 254 nm). 
1
H NMR (600 MHz, CDCl3): δ 1.30-1.60 
(m, 6H), 2.25 (m, 1H), 3.25-3.20 (m, 4H), 3.55-3.65 (m, 2H), 
4.15-4.20 (m, 1H), 4.75-4.80 (m, 1H), 4.95-5.05 (m, 1H), 7.15-
7.25 (m, 5H), 7.30-7.45 (m, 7H), 7.95-8.10 (m, 1H), 8.25-8.35 
(m, 2H), 8.40-8.50 (m, 1H). 
13
C NMR (151 MHz, CDCl3): δ 13.9, 
21.7, 29.6, 37.7, 51.5, 53.1, 57.4, 64.8, 68.6, 86.7, 122.3, 123.4, 
123.6, 125.8, 126.7, 127.7, 128.2, 128.7, 128.8, 129.2, 129.3, 
130.9, 131.2, 132.2, 135.1 139.7, 147.7, 169.1, 171.5, 173.9. 
ESI-HRMS: Calcd. for C27H27N4O6  M+H
+
 503.1931; found 
503.1928. 
Synthesis of tert-butyl 2-(1-(cyclohexylamino)-1-oxo-3-
phenylpropan-2-yl)-2-(4-nitrobenzyl)hydrazinecarboxylate 
(30) 
To a glass vial containing 1 M solution of p-nitro benzaldehyde 
(21 mg, 0.14 mmol) in dry toluene under nitrogen were added 
N
β
-Boc-L-hPhe-OH (50 mg, 0.18 mmol) and cyclohexyl 
isocyanide (22 µL, 0.18 mmol). Reaction was stirring for 4 h 
under reflux (110 °C). The reactions were concentrated under 
reduced pressure and reaction mixtures were purified by flash 
column chromatography using petrol ether/ethyl acetate 2:1. 
Yield: 20 % (18 mg); yellow oil; Rf = 0.32 (petrol ether/ethyl 
acetate 2:1, v/v). 
1
H NMR (600 MHz, CDCl3): δ 1.30-1.45 (m, 
17H), 2.95-3.20 (m, 2H), 3.30-3.80 (m, 3H), 4.10 (br s, 1H), 
4.20-4.40 (br s, 1H), 5.85-6.10 (br s, 1H), 7.15-7.20 (m, 2H), 
7.30-7.45 (m, 2H), 7.55-7.80 (m, 2H), 8.10-8.30 (m, 4H). 
13
C 
NMR (151 MHz, CDCl3): δ 24.9, 25.4, 25.7, 28.0, 28.1, 28.2, 
28.3, 29.7, 32.5, 48.3, 48.7, 55.3, 65.3, 83.5, 123.6, 124.0, 
127.6, 128.3, 128.8, 129.0, 129.3, 129.5, 155.7, 165,4, 168.0. 
MS (ESI+): m/z = 497.1 ESI-HRMS: Calcd. for C27H35N4O5 M-H
-
 
495.2607; found 495.2609. 
Synthesis of tert-butyl 2-(2-(cyclohexylamino)-1-(4-
nitrophenyl)-2-oxoethyl)-2-((S)-1-methoxy-1-oxo-3-
phenylpropan-2-yl)hydrazinecarboxylate (31) 
To a glass vial containing 1 M solution of p-nitro benzaldehyde 
(16.5 mg, 0.11 mmol) in MeOH under nitrogen were added N
β
-
Boc-L-hPhe-OH (31 mg, 0.11 mmol) and the isocyanide (13 µL, 
0.11 mmol), and solution was allowed to stir for 24 h. The 
reaction was concentrated under reduced pressure and 
reaction mixture was purified by flash column chromatography 
using petrol ether/ethyl acetate 2:1. Yield (14 mg; 25 %); 
brown oil; Rf= 0.57  (petrol ether/ethyl acetate 2:1, v/v). 
1
H 
NMR (600 MHz, CDCl3): δ 1.34 (s, 9H), 1.55-1.80 (m, 10H), 
2.95-3.05 (m, 2H), 3.55-3.65 (m, 1H), 3.72 (s, 3H), 3.75-3.85 (m, 
1H), 4.55-4.70 (br s, 1H), 7.25–7.36 (m, 5H), 7.55-7.70 (m, 2H), 
8.8.05-8.15 (br s, 1H), 8.20-8.25 (m, 2H).  
13
C NMR (151 MHz, 
CDCl3): δ 24.2, 24.3, 24.4, 24.9, 27.6, 27.9, 31.6, 31.8, 32.4, 
36.1, 42.0, 43.0, 47.9, 48.0, 51.5, 51.8, 53.0, 69.0 72.6, 73.5, 
74.3, 80.2, 80.8, 122.8, 123.1, 123.4, 126.5, 126.8, 128.0, 
128.3, 129.0, 130.4, 136.9, 141.3, 147.4, 155.6, 167.9, 173.0. 
MS (ESI+): m/z = 555. ESI-HRMS: Calcd. for C29H39N4O7 M+H
+
 
555.2819; found 555.2820. 
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